How do you decide between adjuvant trastuzumab vs trastuzumab/pertuzumab in a patient with localized HER2+ breast cancer post neoadjuvant TCHP who has achieved a pCR?  

After the TRYPHAENA trial, TCHP became the standard of care neoadjuvant regimen for patients with Her-2+ localized breast cancer that was either LN+ or >2 cm in size primary tumor. This was based on a superior pCR rate of 67% compared to other regimens on this study. The standard of care at this ...